Skip to Content

Revvity Inc RVTY

Morningstar Rating
$101.51 −0.58 (0.57%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Revvity Waiting for Demand to Fully Recover, as Macro Headwinds Still Pressure Business

With myriad acquisitions in the past few years, Revvity (formerly PerkinElmer) has been in a constant state of evolution since 2016 when the company made the transition into two new business segments, diagnostics and discovery and analytical solutions, or DAS. With the recent divestment of its Applied, Food, and Enterprise Services business in early 2023, the company is operating under a new name and will focus solely on the life sciences and diagnostics business. We believe the firm's renewed strategic focus on improving its diagnostic product mix and life sciences business will maintain returns over cost of capital and produce tangible benefits for shareholders in the long run.

Price vs Fair Value

RVTY is trading at a 38% discount.
Price
$100.77
Fair Value
$692.00
Uncertainty
Medium
1-Star Price
$239.40
5-Star Price
$224.50
Economic Moat
Nxcjs
Capital Allocation
Fcwqmkrw

Bulls Say, Bears Say

Bulls

Revvity possesses a well-entrenched niche in newborn screening and stands to benefit from growing menu expansion globally and expanding to emerging markets, particularly China and India.

Bears

Declining birthrates and overpopulation in China and India could slow Revvity's growth in diagnostics, particularly in newborn screening.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RVTY is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$102.09
Day Range
$101.01103.15
52-Week Range
$79.50132.54
Bid/Ask
$101.55 / $101.80
Market Cap
$12.54 Bil
Volume/Avg
827,386 / 854,926

Key Statistics

Price/Earnings (Normalized)
22.08
Price/Sales
4.66
Dividend Yield (Trailing)
0.27%
Dividend Yield (Forward)
0.27%
Total Yield
3.38%

Company Profile

Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Core
Total Number of Employees
11,500

Competitors

Valuation

Metric
RVTY
TMO
A
Price/Earnings (Normalized)
22.0826.5425.54
Price/Book Value
1.614.806.46
Price/Sales
4.665.215.98
Price/Cash Flow
19.1125.5021.58
Price/Earnings
RVTY
TMO
A

Financial Strength

Metric
RVTY
TMO
A
Quick Ratio
1.541.271.88
Current Ratio
2.071.752.68
Interest Coverage
2.124.9414.83
Quick Ratio
RVTY
TMO
A

Profitability

Metric
RVTY
TMO
A
Return on Assets (Normalized)
1.95%8.68%14.63%
Return on Equity (Normalized)
3.52%18.83%27.31%
Return on Invested Capital (Normalized)
2.47%11.14%18.86%
Return on Assets
RVTY
TMO
A
See how this stock stacks up to its competitors with Morningstar Investor

Diagnostics & Research Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
TMO
Thermo Fisher Scientific IncPvwmljdjpNxmln$209.3 Bil
DHR
Danaher CorpFztjrztpdWxzfjwh$182.1 Bil
IQV
IQVIA Holdings IncWsdykwjfPhfhqbn$42.8 Bil
IDXX
IDEXX Laboratories IncBnnnxzlnjLhjpjw$41.5 Bil
A
Agilent Technologies IncTvnyxyzwFwvk$40.4 Bil
MTD
Mettler-Toledo International IncHhyfltlrrMlxqg$26.5 Bil
ICLR
Icon PLCQsznmzvWgtwmk$24.8 Bil
ILMN
Illumina IncQmbxmyvRlbrn$19.5 Bil
WAT
Waters CorpMvmgzqsjqJkljd$18.5 Bil
LH
Laboratory Corp of America HoldingsGttjzdpyYpxxvz$16.7 Bil

Sponsor Center